



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Sensitivity and specificity of the ECAS in Parkinson's disease and Progressive Supranuclear Palsy

Citation for published version:

Foley, JA, Niven, EH, Paget, A, Bhatia, KP, Farmer, SF, Jarman, PR, Limousin, P, Warner, TT, Morris, HR, Bak, T, Abrahams, S & Cipelotti, L 2018, 'Sensitivity and specificity of the ECAS in Parkinson's disease and Progressive Supranuclear Palsy' *Parkinson's Disease*, vol 2018, 2426012. DOI: 10.1155/2018/2426012

Digital Object Identifier (DOI):

[10.1155/2018/2426012](https://doi.org/10.1155/2018/2426012)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Parkinson's Disease

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Research Article

Sensitivity and Specificity of the ECAS in Parkinson's Disease and Progressive Supranuclear Palsy

Jennifer A. Foley ^{1,2}, Elaine H. Niven,³ Andrew Paget,¹ Kailash P. Bhatia,^{1,2}
Simon F. Farmer,^{1,2} Paul R. Jarman,^{1,2} Patricia Limousin,^{1,2} Thomas T. Warner,^{1,4}
Huw R. Morris ^{1,5}, Thomas H. Bak ^{6,7,8}, Sharon Abrahams,^{6,7,8} and Lisa Cipolotti ^{1,2,9}

¹National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

²UCL Institute of Neurology, Queen Square, London, UK

³School of Social Sciences (Psychology), University of Dundee, Dundee, UK

⁴Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, Queen Square, London, UK

⁵Department of Clinical Neuroscience, UCL Institute of Neurology, Queen Square, London, UK

⁶Human Cognitive Neuroscience-PPLS, University of Edinburgh, Edinburgh, UK

⁷Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

⁸Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK

⁹Dipartimento di Scienze Psicologiche, Pedagogiche e della Formazione, Università degli Studi di Palermo, Palermo, Italy

Correspondence should be addressed to Lisa Cipolotti; l.cipolotti@ucl.ac.uk

Received 9 October 2017; Accepted 19 April 2018; Published 9 May 2018

Academic Editor: Xiao-Ping Wang

Copyright © 2018 Jennifer A. Foley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disentangling Parkinson's disease (PD) and progressive supranuclear palsy (PSP) may be a diagnostic challenge. Cognitive signs may be useful, but existing screens are often insufficiently sensitive or unsuitable for assessing people with motor disorders. We investigated whether the newly developed ECAS, designed to be used with people with even severe motor disability, was sensitive to the cognitive impairment seen in PD and PSP and able to distinguish between these two disorders. Thirty patients with PD, 11 patients with PSP, and 40 healthy controls were assessed using the ECAS, as well as an extensive neuropsychological assessment. The ECAS detected cognitive impairment in 30% of the PD patients, all of whom fulfilled the diagnostic criteria for mild cognitive impairment. The ECAS was also able to detect cognitive impairment in PSP patients, with 81.8% of patients performing in the impaired range. The ECAS total score distinguished between the patients with PSP and healthy controls with high sensitivity (91.0) and specificity (86.8). Importantly, the ECAS was also able to distinguish between the two syndromes, with the measures of verbal fluency offering high sensitivity (82.0) and specificity (80.0). In sum, the ECAS is a quick, simple, and inexpensive test that can be used to support the differential diagnosis of PSP.

1. Introduction

It has now been over 50 years since progressive supranuclear palsy (PSP) was first described as a progressive neurological disorder with motor, ocular, and cognitive features [1]. Clinically, it remains difficult to distinguish from Parkinson's disease (PD) [2, 3], particularly in the early stages [4]. Even when using agreed criteria, the accuracy of diagnosis is not 100% [5]. As it has a significantly worse prognosis than PD, with a more rapid progression [6], early detection is crucial for enabling access to appropriate interventions and

support, as well as identifying patients suitable for clinical trials. In the absence of any disease-specific biomarkers, there is a need for a quick, simple, and inexpensive test that can be used for the differential diagnosis of PSP.

Both PSP and PD are characterised by extrapyramidal syndromes, each of which can comprise symptoms of bradykinesia, rigidity, and/or postural instability [7]. Both disorders can feature eye movement abnormalities, and although the presence of the supranuclear vertical gaze palsy in PSP is diagnostically helpful, it is not universal [8, 9] and may be absent until quite late in the disease [10]. Although

both disorders are thought to feature some similar cognitive signs, there is evidence to suggest that the specific cognitive profile may be a useful distinguishing feature [11].

Early cognitive impairment is a feature of PSP, which may precede the motor or ocular signs [12]. The profile is mainly that of executive dysfunction [13] and cognitive slowing [14], with markedly reduced verbal fluency [15, 16]. Deficits in other domains, including memory [17], language [18–20], visuospatial [16, 18], and social cognition [21–23], have also been reported.

In contrast, early stages of PD are characterised by only mild deficits in executive functions [24–27], but with illness progression, there is evolution from a mild cognitive impairment (MCI) to dementia, with greater involvement of posterior-based visual functions [28–30].

Existing screens of cognitive functioning can be criticised for being insufficiently sensitive to the cognitive profile of both PD and PSP. For example, the most widely used cognitive screen, the MMSE [31], has no measure of verbal fluency. Both the MMSE and the Addenbrooke's Cognitive Examination [32] have inadequate assessment of executive function. Their ensuing ceiling effects give them a low detection rate for cognitive impairment in Parkinsonian syndromes [33–35]. The Frontal Assessment Battery [36] does assess verbal fluency and executive function but has no measure of memory, language, or visuospatial function. Similarly, the Dementia Rating Scale (DRS) [37] has no measure of language or visuospatial function. This reliance upon the executive functions reduces its ability to discriminate PSP from PD [38] or frontotemporal syndromes [39]. The DRS also has a lengthy administration time and requires specialised testing materials, impractical for routine bedside use. The Montreal Cognitive Assessment [40] does have a measure of verbal fluency but does not accommodate for physical disability. Indeed, none of the existing assessments were designed specifically for people with movement disorders, such as Parkinsonian syndromes. Tasks involving speaking, writing, or drawing can be influenced by motor symptoms such as tremor, rigidity, bradykinesia, apraxia, or dysarthria; thus, a genuine cognitive impairment might be sometimes difficult to distinguish from motor dysfunction and performance decrements exaggerated by physical disability.

The ECAS [41] was recently developed as a brief assessment for the identification of cognitive and behavioural changes in disorders characterised by prominent motor symptoms, such as amyotrophic lateral sclerosis (ALS). It was developed to be used with patients with even severe physical disability and thus may be suitable for detecting cognitive impairment in all motor disorders. Many of the subtests can be performed either orally or manually, with some measures corrected for motor speed, reducing the impact that physical disability may have upon performance on cognitive tests [42]. It also allows the clinician to track cognitive impairment throughout the disease course, crucial for any longitudinal studies.

The ECAS has been standardised using a sample of healthy controls, providing normative data for clinical use [41]. It has also been validated against other screening tools

[43, 44] and extensive neuropsychological assessment [45]. It is available in English [41], German [46], Swiss German [46], Italian [44], and Chinese [47]. However, it remains untested whether the ECAS is also sensitive to the cognitive impairment observed in other progressive movement disorders. Thus, the aims of the present study were to determine firstly whether the ECAS is sensitive to the cognitive impairment seen in PD and PSP and secondly whether it is able to distinguish between these disorders, in order to support the differential diagnosis of PSP.

2. Methods

2.1. Participants. All patients were recruited from the National Hospital for Neurology and Neurosurgery, Queen Square, London. PSP patients (9 males and 2 females) were diagnosed using the NINDS-SPSP criteria [48] and had a mean illness duration of 3.73 years (range 1–11 years). PD patients (24 males and 6 females) fulfilled the Queen Square Brain Bank criteria for PD and had a mean illness duration of 5.67 years (range 0–14 years). All patients with PD-MCI were identified using the Movement Disorder Society Task Force guidelines [49], in which impairment (<2 SD) is present on at least two tests of cognitive functioning, either within or across different cognitive domains.

The healthy controls were those reported by Niven et al. [45]. They (26 males and 14 females) were recruited through the Psychology Department of the University of Edinburgh. No participant had significant neurological or psychiatric history.

The research was done in accordance with the Declaration of Helsinki and approved by the NRES Committee London-Queen Square and the University of Edinburgh's Department of Psychology Ethics Committee.

2.2. Measures. The ECAS is a 15–20-minute screen that includes assessment of the following domains: (1) fluency (free: words beginning with "S" and fixed: words beginning with "T" but with only four letters); (2) executive functions, separate from verbal fluency (Reverse Digit Span, Alternation, Inhibitory Sentence Completion, and Social Cognition); (3) language (Naming, Comprehension, and Spelling); (4) memory (Immediate Recall, Delayed Percentage Retention, and Delayed Recognition); and (5) visuospatial (Dot Counting, Cube Counting, and Number Location). Verbal fluency measures take into account the slowing of motor responses, by generating a verbal fluency index corrected for motor speed. Previously published ECAS normative data [41] were used to classify the abnormality of performance on each domain and calculate the total score out of a maximum of 136 (lower score indicating worse performance), with any scores <2 SD considered to be impaired.

Extensive neuropsychological testing was administered to assess the same domains (fluency, executive functions, language, memory, and visuospatial; Table 1). Mood was assessed using the Hospital Anxiety and Depression Scale [50], and patients were also assessed using the Apathy Scale [51].

Scores for the neuropsychological assessments were compared with published normative data. For each measure,

TABLE 1: Neuropsychological assessment.

Domain	Subdomain	Measures
Fluency		Phonemic verbal fluency index [42] (VFi): words beginning with "P" and "R"
Executive functions	Inhibition	Hayling Sentence Completion Test [52]: total unconnected errors (converted but not scaled); latency score (time taken to complete unconnected sentences minus time taken for connected sentences)
	Shifting and rule detection	Brixton Spatial Anticipation Test [52]: total number of errors
	Social	Reading the Mind in the Eyes-Revised [53]: total number of correct ones
Language	Naming	Graded Naming Test [54]
	Spelling	Graded Difficulty Spelling Test [55]
Memory		Adult Memory and Information Processing Battery [56]: immediate story recall; delayed story recall
Visuospatial		The Visual Object and Space Perception Battery [57]: cube analysis; number location

TABLE 2: Demographics of the participants.

	PSP patients		PD patients		Controls	
	Mean (SD)	Range	Mean (SD)	Range	Mean (SD)	Range
Age	66.82 (7.08)	53–77	63.33 (7.89)	50–80	62.70 (10.48)	39–88
Duration of symptoms (years)	3.73 (3.20)	1–11	5.67 (3.47)	0–14	—	—
Gender (female)	2	—	6	—	14	—
Education, mean years (SD)	15.27 (4.98)	10–26	14.33 (3.22)	9–23	12.25 (3.39)	9–25
HADS Depression	8.50 (5.50)	1–15	6.77 (4.39)	0–16	2.40 (1.81)	0–6
HADS Anxiety	8.50 (5.79)	2–17	9.17 (4.13)	3–18	4.83 (2.75)	0–11
Apathy	17.67 (12.04)	4–34	15.90 (10.26)	4–42	—	—

HADS: Hospital Anxiety and Depression Scale.

patients were judged to be impaired if scores were ≤ 2 SD. In the case where multiple measures were used, performance was classified as impaired when ≤ 2 SD on one of the two or two of the three measures was used.

2.3. Statistical Analyses. Data were analysed using SPSS v.19. Between-group comparisons were made using analyses of variance, and Pearson's and Spearman's correlations were used to detail the relationships between measures. Receiver operating characteristic (ROC) curve analyses were used to determine the relative sensitivity and specificity of the ECAS for the two patient groups.

3. Results

3.1. Demographics. Demographic details are given in Table 2. There were no significant group differences in age or education, and patients did not differ in symptom duration. There were significant group effects found for both HADS Anxiety ($F(2, 75) = 13.04$; $p < 0.001$) and Depression ($F(2, 77) = 19.03$; $p < 0.001$), with post hoc analysis revealing that patients had significantly higher burden of symptoms than healthy controls but no significant group difference between patient groups. There was no significant group difference in apathy scores between patient groups.

3.2. Performance on the ECAS. There was a significant effect of diagnosis on ECAS performance (Table 3). PSP patients had significantly lower total scores than PD patients and healthy controls, and PD patients had significantly lower

total scores than healthy controls (all $p < 0.017$). There was a significant effect of diagnosis on all domains, except visuospatial. PSP patients performed worse than PD patients and healthy controls on fluency, language, executive function, and memory (all $p < 0.017$). PD patients performed worse than healthy controls on executive function only ($p < 0.017$).

When compared to published normative data, 81.8% ($n = 9$) of the PSP patients and 30.0% of the PD patients ($n = 9$) were impaired on the ECAS. PSP patients demonstrated most frequent impairments in fluency, language, and memory (each $n = 7$; 63.6%) and then executive function ($n = 6$; 54.5%) and visuospatial ($n = 3$; 27.3%). PD patients demonstrated most frequent impairments in language ($n = 9$; 30.0%), executive function and memory (each $n = 8$; 26.7%), and then fluency and visuospatial (each $n = 5$; 16.7%). There were no significant correlations between duration of symptoms and ECAS scores in either patient groups.

In order to investigate the specific nature of the impairment in both patient groups, individual domains were further investigated. In fluency, post hoc comparisons revealed a significant effect of diagnosis on both free fluency ($F(2, 23.16) = 15.19$; $p < 0.017$) and fixed fluency ($F(2, 21.63) = 8.30$; $p < 0.017$), with PSP patients performing worse than PD patients and healthy controls (all $p < 0.017$), but with no significant differences between PD patients and healthy controls. In language, there was a significant group effect on spelling ($F(2, 76) = 10.58$; $p < 0.017$), with PSP patients performing worse than PD

TABLE 3: ECAS scores of the participants.

	PSP patients		PD patients		Controls		<i>F</i> (df)	<i>p</i>
	Mean (SD)	Range	Mean (SD)	Range	Mean (SD)	Range		
Total (max. 136)	85.09 (24.46)	54–126	109.87 (13.52)	78–126	120.61 (7.06)	100–132	17.44 (2, 22.09) ^a	<0.001
Executive function (max. 48)	29.27 (13.27)	9–46	36.93 (6.05)	19–44	42.11 (3.49)	33–48	12.56 (2, 22.22) ^a	<0.001
Language (max. 28)	23.18 (5.06)	15–28	26.67 (2.11)	19–28	27.50 (0.80)	25–28	5.76 (2, 21.01) ^a	<0.001
Fluency (max. 24)	8.18 (8.74)	0–22	18.73 (4.83)	6–24	20.74 (2.39)	12–24	12.37 (2, 21.91) ^a	<0.001
Memory (max. 24)	10.27 (6.90)	0–20	15.67 (4.25)	3–22	18.39 (2.53)	13–23	10.85 (2, 22.76) ^a	<0.001
Visuospatial (max. 12)	11.09 (1.87)	6–12	11.47 (1.04)	8–12	11.87 (0.67)	8–12	2.33 (2, 22.86) ^a	0.066

^aWelch's adjusted *F* ratio.

TABLE 4: Neuropsychological assessment performance of participants.

		PSP patients		PD patients		Healthy controls		<i>F</i> (df)	<i>p</i>	Post hoc
		Mean (SD)	Range	Mean (SD)	Range	Mean (SD)	Range			
Fluency	“P” VFi	10.90 (6.30)	2.37–19.67	4.13 (2.98)	0.96–14.50	3.68 (1.96)	1.52–9.33	22.65 (2.78)	<0.001	PSP < PD
	“R” VFi	14.16 (13.16)	2.50–41.00	4.12 (2.11)	2.00–9.50	3.65 (1.73)	1.72–9.33	22.37 (2.76)	<0.001	PSP < PD
Executive function	Hayling: B–A time	69.14 (86.55)	5–251	33.00 (28.04)	–3 to 126	34.88 (28.96)	–5 to 121	2.88 (2.73)	0.06	
	Hayling: errors	6.57 (5.56)	0–14	5.17 (5.89)	0–29	8.75 (9.17)	0–32	1.80 (2.73)	0.17	
	Brixton	38.43 (3.21)	35–43	34.54 (9.71)	16–50	35.08 (8.23)	15–47	0.59 (2.70)	0.56	
	Reading the Mind in the Eyes	20.50 (5.43)	14–29	23.93 (5.06)	13–35	26.35 (3.81)	17–34	5.72 (2.71)	<0.01	PSP < HC
Language	Graded Naming Test	20.64 (5.85)	9–26	23.20 (3.61)	13–29	24.15 (6.64)	14–57	1.71 (2.78)	0.19	
	Graded Difficulty Spelling Test	19.64 (8.44)	2–29	22.29 (6.01)	7–30	22.53 (4.50)	12–29	1.15 (2.76)	0.32	
Memory	Immediate Story Recall	24.45 (14.20)	0–41	27.04 (9.73)	7–49					
	Delayed Story Recall	23.64 (15.54)	0–40	25.46 (9.61)	7–46					
	Retention	80.16 (32.96)	0–111.11	93.92 (14.75)	62.50–136.00	94.49 (12.74)	58.82–12.27	3.12 (2.77)	0.05	
Visuospatial	Cube Analysis	8.91 (1.58)	6–10	8.83 (1.62)	5–10	9.63 (0.87)	5–10	23.61 (2.78)	<0.05	PSP < HC
	Number Location	8.45 (2.46)	2–10	9.20 (1.00)	7–10	9.43 (0.71)	7–10	2.90 (2.78)	0.06	

VFi: Verbal Fluency Index.

patients and healthy controls (both $p < 0.017$), but with no significant difference between PD patients and healthy controls. In memory, there was a significant group effect on immediate recall ($F(2, 24.04) = 11.47$; $p < 0.017$) and retention ($F(2, 20.69) = 8.92$; $p < 0.017$), but not recognition. PSP patients performed significantly worse than PD patients and healthy controls on both of these (both $p < 0.017$), but with no significant difference between PD patients and healthy controls. In executive functions, there were significant group effects on reverse digit span ($F(2, 25.96) = 7.60$; $p < 0.017$), alternation ($F(2, 22.92) = 5.66$; $p < 0.017$), and social cognition ($F(2, 20.42) = 9.49$; $p < 0.017$). Both PSP and PD patients performed significantly worse than healthy controls on reverse digit span and social cognition (all $p < 0.017$), but with no significant differences between patient

groups. PSP patients performed significantly worse than PD patients and healthy controls on alternation ($p < 0.017$), but with no significant difference between PD patients and healthy controls.

3.3. Performance on Full Neuropsychological Assessment. Upon full neuropsychological assessment, there was a significant effect of diagnosis on fluency, executive function, and visuospatial domains (Table 4). Specifically, there were significant group differences on both measures of fluency, with PSP patients performing worse than PD patients and healthy controls. There were no significant differences between PD patients and healthy controls. In addition, PSP patients performed worse than healthy controls on the

Reading the Mind in the Eyes Test and Cube Analysis, but with no significant differences between PSP and PD patients, or between PD patients and healthy controls.

When scores on each of the neuropsychological assessments were compared with published normative data, there was a significant group difference in incidence of impairment in one domain only: fluency ($\chi^2(1) = 7.61; p < 0.001$). Nine of the 11 PSP patients (81.8%) were classified as impaired on at least one measure of verbal fluency, in comparison with only 33.3% ($n = 10$) of the 30 PD patients.

3.4. Diagnostic Accuracy of the ECAS for Cognitive Impairment in PD. Within the PD patients, a total of 17 (56.67%) met the criteria for PD-MCI. When PD and PD-MCI groups were compared, there were no significant differences in age, education, or symptom duration. However, on the ECAS, the PD-MCI group had significantly lower total scores ($t(20.25) = 5.14; p < 0.001$) and performed worse on executive function ($t(23.83) = 3.02; p < 0.01$), verbal fluency ($t(22.52) = 3.26; p < 0.01$), memory ($t(28) = 3.09; p < 0.01$), and visuospatial subscales ($t(16.00) = 3.11; p < 0.01$). On full neuropsychological assessment, the PD-MCI group also performed significantly worse on the Brixton Test ($t(24) = 3.81; p < 0.001$), Reading the Mind in the Eyes Test ($t(26) = 2.75; p < 0.05$), Graded Naming Test ($t(28) = 4.32; p < 0.001$), and Cube Analysis ($t(20.69) = 2.801; p < 0.05$).

ROC curve analysis revealed that the total score of the ECAS is able to discriminate between PD and PD-MCI with high sensitivity (88.2%) and 100% specificity, when using a threshold score of 112.50/136. The AUC is 0.93 (SE = 0.06; $p < 0.001$). Confidence intervals are 0.81 (lower bound) and 1.00 (upper bound). Indeed, all PD patients who performed in the impaired range on the ECAS fulfilled the diagnostic criteria for PD-MCI.

3.5. Diagnostic Accuracy of the ECAS for PSP. ROC curve analysis also revealed that the ECAS is highly specific (86.8%) and sensitive (91.0%) when discriminating PSP patients from healthy controls using a threshold score of 113.50/136. The AUC is 0.91 (SE = 0.67; $p < 0.001$). Confidence intervals are 0.79 (lower bound) and 1.00 (upper bound). All PSP patients who performed in the impaired range on the ECAS demonstrated impairment upon full neuropsychological testing, including impairment on at least one measure of verbal fluency.

3.6. Diagnostic Accuracy of the ECAS for Distinguishing between PD and PSP. The second aim of the study was to determine whether the ECAS is able to distinguish between PD and PSP, in order to support the early and accurate diagnosis of PSP. ROC curve analysis showed that the measure is able to discriminate between PD and PSP (when comparing all patients, irrespective of cognitive performance), with high specificity (76.7%) and sensitivity (72.7%), using a threshold score of 103.50/136 (Figure 1). The AUC is 0.80 (SE = 0.09; $p < 0.01$). Confidence intervals are 0.62 (lower bound) and 0.98 (upper bound). This




FIGURE 1: ROC curve depicting sensitivity and specificity of the ECAS, when comparing the PD and PSP patients (higher sensitivity scores indicate lower performance).

generated three false negatives and seven false positives. The false positives were all patients who fulfilled the criteria for PD-MCI.

Within the ECAS, fluency was the best predictor of PSP, with high specificity (80.0%) and sensitivity (82.0%) using a threshold score of 17/24. The AUC is 0.84 (SE = 0.08; $p < 0.01$). Confidence intervals are 0.69 (lower bound) and 1.00 (upper bound). This generated two false negatives and six false positives (five PD-MCI and one PD). This is in contrast to when using the raw number of words generated in the two fluency tasks as a predictor, which has lower sensitivity (77.8%) and specificity (79.2%) when using a threshold score of 17.5.

4. Discussion

Our study has shown that the ECAS is sensitive to the cognitive impairment seen in PD. We found that 30% of PD patients were impaired on the ECAS, all of whom also demonstrated impairments upon full neuropsychological testing and fulfilled the criteria for PD-MCI. Indeed, ROC curve analyses revealed that the ECAS has excellent sensitivity and complete specificity for detection of PD-MCI. On the ECAS, PD patients demonstrated impairments in a number of domains but performed significantly worse than healthy controls on one domain only: executive function. PD-MCI patients also demonstrated deficits in language and visuospatial functioning. These findings confirm the greater involvement of posterior functions with more advanced Parkinson's disease [30] but also suggest that the pattern of impairment can be fairly heterogeneous, even involving language. This is in accordance with the findings of the MDS Task Force [49], who also report impairments in a range of cognitive domains, including language.

Our data also show that the ECAS is sensitive to the cognitive impairment in PSP. We found that 81.8% of PSP patients were impaired on both the ECAS and full neuropsychological testing, including at least one measure of

fluency. Again, ROC curve analyses confirmed that the ECAS total score gave excellent sensitivity and specificity for detection of PSP when compared with healthy controls. On the ECAS, PSP patients demonstrated the expected impairment in fluency, but also executive function, memory, and language. On extensive neuropsychological testing, PSP patients demonstrated impairments in fluency as well as executive function and visuospatial. The prominence of fluency and executive impairment on both the ECAS and full neuropsychological testing is in accordance with previous descriptions [13, 15, 16, 28], confirming that the ECAS is sensitive to the typical profile of cognitive impairment in PSP.

Importantly, we also found that the ECAS was able to distinguish between PD and PSP. ROC curve analysis revealed that the ECAS total score was sensitive and specific to PSP, with verbal fluency being the best discriminator. The ECAS was able to identify all PSP cases demonstrating cognitive impairment upon full testing. The few false positives mostly reflected PD patients with advanced cognitive impairment.

The strikingly reduced verbal fluency found on the ECAS and full testing confirms this as the cognitive hallmark of PSP. Importantly, the ECAS revealed this marked deficit even after accounting for the slowed motor speed. This contrasts with impairments in other cognitive domains, such as memory, which can improve by up to 50% given sufficient extra time [58, 59]. This impoverished verbal fluency, alongside the frequent family reports of reduced spontaneous speech and conversation initiation, likely reflects a cognitive adynamia beyond that of simple bradyphrenia but rather a more significant impairment in the generation of a “fluent sequence of novel thought” [19, 60]. This may reflect a deficit in novel thought generation and/or its appropriate sequencing [61]. Indeed, it has been argued that the akinesia in motor abilities, reduction of verbal fluency in cognition, and apathy in behaviour are all different manifestations of the same underlying disorder [62].

PSP patients also demonstrated impairments in other domains, which supports the findings of previous studies. In accordance with previous reports of poor delayed recall [17], our PSP patients displayed impaired verbal recall on the ECAS, with three of the seven PSP patients impaired on both the ECAS and full testing. Our patients also demonstrated language impairment, reflecting spelling difficulties, in accordance with previous studies [20, 63, 64]. Spelling was more impaired on the ECAS, perhaps because its spelling test comprises nouns, verbs, and compounds of low-to-medium frequency, with a longer mean length. In contrast, the spelling test used upon full testing contained mostly nouns of high-to-low frequency, with a shorter mean length. Our patients also demonstrated impaired visuospatial function, which supports previous findings [16, 18]. Nearly a third of PSP patients were impaired on the ECAS, with all of these also impaired upon full testing.

The PD and PSP patients both performed poorly on measures of social cognition. These findings echo previous reports of impaired performance on tests of theory of mind and social norms [22, 44, 65–67].

5. Conclusions

The ECAS captures the core cognitive deficit of reduced verbal fluency, as well as the wider cognitive profile of PSP. This may allow longitudinal testing to track progression as verbal fluency reaches floor. It was possible to use the ECAS with all the patients who took part in this study, despite often severe motor symptoms, indicating that it would be well tolerated in those with advanced disease. This suggests that the ECAS is suited for bedside use for detecting cognitive impairment in Parkinsonian syndromes and for distinguishing different cognitive profiles within these, in order to support differential diagnosis. Full neuropsychological assessment can then be used to further elucidate the specific clinical profile of each patient. Future research should examine its sensitivity for detecting cognitive impairment in other progressive movement disorders.

Conflicts of Interest

The authors declare that there are no known conflicts of interest.

Acknowledgments

The authors thank Dr. Francisco Musich for his assistance with data collection. Part of this research was supported by an award from the Motor Neurone Disease Association (Sharon Abrahams/Apr11/6070). The study sponsor funded the testing of the control participants, as part of a larger study investigating the use of the ECAS in ALS.

References

- [1] J. C. Steele, J. C. Richardson, and J. Olszewski, “Progressive supranuclear palsy,” *Archives of Neurology*, vol. 10, no. 4, pp. 333–359, 1964.
- [2] T. H. Bak and J. R. Hodges, “The neuropsychology of progressive supranuclear palsy,” *Neurocase*, vol. 4, no. 2, pp. 89–94, 1998.
- [3] I. Litvan, Y. Agid, J. Jankovic et al., “Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome),” *Neurology*, vol. 46, no. 4, pp. 922–930, 1996.
- [4] R. George, V. Krishnan, B. Mohan, and P. Maniyar, “Parkinson's disease and early stages of progressive supranuclear palsy: a neurological mimicry,” *Journal of Case Reports*, vol. 5, pp. 377–381, 2015.
- [5] A. J. Hughes, S. E. Daniel, Y. Ben-Shlomo, and A. J. Lees, “The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service,” *Brain*, vol. 125, no. 4, pp. 861–870, 2002.
- [6] S. S. O'Sullivan, L. A. Massey, D. R. Williams et al., “Clinical outcomes of progressive supranuclear palsy and multiple system atrophy,” *Brain*, vol. 131, no. 5, pp. 1362–1372, 2008.
- [7] D. R. Williams and A. J. Lees, “Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges,” *Lancet Neurology*, vol. 8, no. 3, pp. 270–279, 2010.
- [8] I. Litvan, D. A. Grimes, A. E. Lang et al., “Clinical features differentiating patients with post-mortem confirmed progressive supranuclear palsy and corticobasal degeneration,” *Journal of Neurology*, vol. 246, pp. III–II5, 1999.

- [9] E. H. Pinkhardt, R. Jurgens, W. Becker, F. Valdarno, A. C. Ludolph, and J. Kassubek, "Differential diagnostic value of eye movement recording in PSP-parkinsonism, Richardson's syndrome, and idiopathic Parkinson's disease," *Journal of Neurology*, vol. 255, no. 12, pp. 1916–1925, 2008.
- [10] D. R. Williams, R. de Silva, D. C. Paviour et al., "Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism," *Brain*, vol. 128, no. 6, pp. 1247–1258, 2005.
- [11] R. G. Brown, L. Lacomblez, B. G. Landwehrmeyer et al., "Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy," *Brain*, vol. 133, no. 8, pp. 2382–2393, 2010.
- [12] L. Donker Kaat, A. J. W. Boon, W. Kamphorst, R. Ravid, H. J. Duivenvoorden, and J. C. van Swieten, "Frontal presentation in progressive supranuclear palsy," *Neurology*, vol. 69, no. 8, pp. 723–729, 2007.
- [13] B. Pillon, B. Dubois, A. Ploska, and Y. Agid, "Severity and specificity of cognitive impairment in Alzheimer's, Huntington's and Parkinson's diseases and progressive supranuclear palsy," *Neurology*, vol. 41, no. 5, pp. 634–643, 1991.
- [14] B. Dubois, B. Pillon, F. Legault, Y. Agid, and F. Lhermitte, "Slowing of cognitive processing in progressive supranuclear palsy: a comparison with Parkinson's disease," *Archives of Neurology*, vol. 45, no. 11, pp. 1194–1199, 1998.
- [15] T. H. Bak, L. M. Crawford, V. C. Hearn, P. S. Mathuranath, and J. R. Hodges, "Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA)," *Neurocase*, vol. 11, no. 4, pp. 268–273, 2005.
- [16] T. Rittman, B. C. Ghosh, P. McColgan et al., "The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders," *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 84, no. 5, pp. 544–551, 2013.
- [17] M. Zarei, H. R. Pouretamad, T. Bak, and J. R. Hodges, "Autobiographical memory in progressive supranuclear palsy," *European Journal of Neurology*, vol. 17, no. 2, pp. 238–241, 2010.
- [18] T. H. Bak, D. Caine, V. C. Hearn, and J. R. Hodges, "Visuospatial functions in atypical parkinsonian syndromes," *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 77, no. 4, pp. 454–456, 2006.
- [19] G. Robinson, T. Shallice, and L. Cipolotti, "Dynamic aphasia in progressive supranuclear palsy: a deficit in generating a fluent sequence of novel thought," *Neuropsychologia*, vol. 44, no. 8, pp. 1344–1360, 2006.
- [20] J. D. Rohrer, D. Paviour, A. M. Bronstein, S. S. O'Sullivan, A. Lees, and J. D. Warren, "Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis," *Movement Disorders*, vol. 25, no. 2, pp. 179–188, 2010.
- [21] B. C. P. Ghosh, J. B. Rowe, A. J. Calder, J. R. Hodges, and T. H. Bak, "Emotion recognition in progressive supranuclear palsy," *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 80, no. 10, pp. 1143–1145, 2009.
- [22] B. C. P. Ghosh, A. J. Calder, P. V. Peers et al., "Social cognitive deficits and their neural correlates in progressive supranuclear palsy," *Brain*, vol. 135, no. 7, pp. 2089–2102, 2012.
- [23] F. M. O'Keefe, B. Murray, R. F. Coen et al., "Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy," *Brain*, vol. 130, no. 3, pp. 753–764, 2007.
- [24] R. Cools, E. Stefanova, R. A. Barker, T. W. Robbins, and A. M. Owen, "Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET," *Brain*, vol. 125, no. 3, pp. 584–594, 2002.
- [25] J. D. E. Gabrieli, J. Singh, G. T. Stebbins, and C. G. Goetz, "Reduced working memory span in Parkinson's disease: evidence for the role of frontostriatal system in working and strategic memory," *Neuropsychology*, vol. 10, no. 3, pp. 322–332, 1996.
- [26] A. McKinlay, R. C. Grace, J. C. Dalrymple-Alford, and D. Roger, "Characteristics of executive function impairment in Parkinson's disease patients without dementia," *Journal of the International Neuropsychological Society*, vol. 16, no. 2, pp. 268–277, 2010.
- [27] J. Uekermann, I. Daum, M. Bielawski et al., "Differential executive control impairments in early Parkinson's disease," in *Journal of Neural Transmission. Supplementa*, T. Müller and P. Riederer, Eds., pp. 39–51, Springer, Berlin, Germany, 2004.
- [28] R. Brown and C. D. Marsden, "Visuospatial function in Parkinson's disease," *Brain*, vol. 109, no. 5, pp. 987–1002, 1986.
- [29] R. S. Weil, A. E. Schrag, J. D. Warren, S. J. Crutch, A. J. Lees, and H. R. Morris, "Visual dysfunction in Parkinson's disease," *Brain*, vol. 139, no. 11, pp. 2827–2843, 2016.
- [30] C. H. Williams-Gray, T. Foltynie, C. E. G. Brayne, T. W. Robbins, and R. A. Barker, "Evolution of cognitive dysfunction in an incident Parkinson's disease cohort," *Brain*, vol. 130, no. 7, pp. 1787–1798, 2007.
- [31] M. F. Folstein, S. E. Folstein, and P. R. McHugh, "“Minimal state”: a practical method for grading the cognitive state of patients for the clinician," *Journal of Psychiatric Research*, vol. 12, no. 3, pp. 189–198, 1975.
- [32] E. Mioshi, K. Dawson, J. Mitchell, R. Arnold, and J. R. Hodges, "The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening," *International Journal of Geriatric Psychiatry*, vol. 21, no. 11, pp. 1078–1085, 2006.
- [33] T. H. Bak, T. T. Rogers, L. M. Crawford, V. C. Hearn, P. S. Mathuranath, and J. R. Hodges, "Cognitive bedside assessment in atypical parkinsonian syndromes," *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 76, no. 3, pp. 420–422, 2005.
- [34] E. Fiorenzato, L. Weis, C. Falup-Pecurariu et al., "Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy," *Journal of Neural Transmission*, vol. 123, no. 12, pp. 1435–1442, 2016.
- [35] T. H. Bak and E. Mioshi, "A cognitive bedside assessment beyond the MMSE: the Addenbrooke's Cognitive Examination," *Practical Neurology*, vol. 7, pp. 245–249, 2007.
- [36] B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon, "The FAB: a Frontal Assessment Battery at bedside," *Neurology*, vol. 55, no. 11, pp. 1621–1626, 2000.
- [37] S. Mattis, *Dementia Rating Scale (DRS)*, Psychological Assessment Resources, Lutz, FL, USA, 1998.
- [38] J. Kulisevsky and J. Pagonabarraga, "Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment," *Movement Disorders*, vol. 24, no. 8, pp. 1103–1110, 2009.
- [39] M. Stamelou, J. Diehl-Schmid, A. Hapfelmeier et al., "The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias," *Parkinsonism and Related Disorders*, vol. 21, no. 10, pp. 1264–1268, 2015.
- [40] Z. S. Nasreddine, N. A. Phillips, V. Bedirian et al., "The Montreal Cognitive Assessment, MoCA: a brief screening tool

- for mild cognitive impairment," *Journal of the American Geriatrics Society*, vol. 53, no. 4, pp. 696–699, 2005.
- [41] S. Abrahams, J. Newton, E. Niven, J. Foley, and T. H. Bak, "Screening for cognition and behaviour changes in ALS," *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 15, no. 1-2, pp. 9–14, 2014.
- [42] S. Abrahams, P. N. Leigh, A. Harvey, G. N. Vythelingum, D. Grise, and L. H. Goldstein, "Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS)," *Neuropsychologia*, vol. 38, no. 6, pp. 734–747, 2000.
- [43] D. Lulé, C. Burkhardt, S. Abdulla et al., "The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross-sectional comparison of established screening tools in a German-Swiss population," *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 16, no. 1-2, pp. 16–23, 2015.
- [44] B. Poletti, F. Solca, L. Carelli et al., "The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)," *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 17, no. 7-8, pp. 489–498, 2016.
- [45] E. Niven, J. Newton, J. Foley et al., "Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders," *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 16, no. 3-4, pp. 172–179, 2015.
- [46] M. Loose, C. Burkhardt, H. Aho-Özhan et al., "Age and education-matched cut-off scores for the revised German/Swiss-German version of ECAS," *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 17, no. 5-6, pp. 374–376, 2016.
- [47] S. Ye, Y. Ji, C. Li, J. He, X. Liu, and F. Dongsheng, "The Edinburgh Cognitive and Behavioural ALS Screen in a Chinese amyotrophic lateral sclerosis population," *PLoS One*, vol. 11, no. 5, article e0155496, 2016.
- [48] I. Litvan, Y. Agid, and D. Calne, "Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop," *Neurology*, vol. 47, no. 1, pp. 1–9, 1996.
- [49] I. Litvan, J. G. Goldman, A. I. Tröster et al., "Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines," *Movement Disorders*, vol. 27, no. 3, pp. 349–356, 2012.
- [50] A. S. Zigmond and R. P. Snaith, "The hospital anxiety and depression scale," *Acta Psychiatrica Scandinavica*, vol. 67, no. 6, pp. 361–370, 1983.
- [51] R. S. Marin, R. C. Biedrzycki, and S. Firinciogullari, "Reliability and validity of the apathy evaluation scale," *Psychiatry Research*, vol. 38, no. 2, pp. 143–162, 1991.
- [52] P. W. Burgess and T. Shallice, *The Hayling and Brixton Tests*, Thames Valley Test Company, Bury St Edmunds, UK, 1997.
- [53] S. Baron-Cohen, S. Wheelwright, J. Hill, Y. Raste, and I. Plumb, "The 'Reading the Mind in the Eyes' Test Revised Version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism," *Journal of Child Psychology and Psychiatry*, vol. 42, no. 2, pp. 241–251, 2001.
- [54] P. McKenna and E. K. Warrington, *Graded Naming Test*, NFER-Nelson, London, UK, 1983.
- [55] D. M. Baxter and E. K. Warrington, "Measuring dysgraphia: a graded-difficulty spelling test," *Behavioural Neurology*, vol. 7, no. 3-4, pp. 107–116, 1994.
- [56] A. K. Coughlan and S. E. Hollows, *The Adult's Memory and Information Processing Battery*, St James' University Hospital, Leeds, UK, 1985.
- [57] E. K. Warrington and M. James, *The Visual Object and Space Perception Battery*, Thames Valley Test Company, Bury St Edmunds, UK, 1991.
- [58] M. L. Albert, R. G. Feldman, and A. L. Willis, "The subcortical dementia of progressive supranuclear palsy," *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 37, no. 2, pp. 121–130, 1974.
- [59] A. Kertesz and P. McMonagle, "Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy," *Journal of the Neurological Sciences*, vol. 289, no. 1-2, pp. 138–143, 2010.
- [60] G. A. Robinson, D. Spooner, and W. J. Harrison, "Frontal dynamic aphasia in progressive supranuclear palsy: distinguishing between generation and fluent sequencing of novel thoughts," *Neuropsychologia*, vol. 77, pp. 62–75, 2015.
- [61] G. A. Robinson, "Primary progressive dynamic aphasia and Parkinsonism: generation, selection and sequencing deficits," *Neuropsychologia*, vol. 51, no. 13, pp. 2534–2547, 2013.
- [62] T. H. Bak, "Movement disorders: why movement and cognition belong together," *Nature Reviews Neurology*, vol. 7, no. 1, pp. 10–12, 2011.
- [63] B. Boeve, D. Dickson, J. Duffy, J. Bartleson, M. Trenerry, and R. Petersen, "Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology," *European Neurology*, vol. 49, no. 2, pp. 72–78, 2003.
- [64] K. A. Josephs and J. R. Duffy, "Apraxia of speech and non-fluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy," *Current Opinion in Neurology*, vol. 21, no. 6, pp. 688–692, 2008.
- [65] M. E. Bodden, R. Dodel, and E. Kalbe, "Theory of mind in Parkinson's disease and related basal ganglia disorders: a systematic review," *Movement Disorders*, vol. 25, no. 1, pp. 13–27, 2010.
- [66] A. Halpin, K. Rascovsky, L. Massimo, D. Irwin, C. McMillan, and M. Grossman, "Evidence of social norm deficits in progressive supranuclear palsy," *Neurology*, vol. 86, no. 16, pp. P5–194, 2016.
- [67] M. Roca, T. Torralva, E. Gleichgerrcht et al., "Impairments in social cognition in early medicated and unmedicated Parkinson disease," *Cognitive and Behavioural Neurology*, vol. 23, no. 3, pp. 152–158, 2010.



Hindawi

Submit your manuscripts at www.hindawi.com

